Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2026)

Royalty Pharma has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $713.2 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities rose 52.68% year-over-year to $713.2 million; the TTM figure through Jun 2026 stood at $713.2 million (up 52.68% YoY), while the FY2025 annual figure was $577.9 million, up 4683.69% from the prior year.
• Other Non-Current Liabilities came in at $713.2 million for Q2 2026 at Royalty Pharma, up from $648.7 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $713.2 million in Q2 2026 to a low of $900000.0 in Q4 2023.
• Average Other Non-Current Liabilities over 5 years is $180.3 million, with a median of $12.3 million recorded in 2023.
• Year-over-year, Other Non-Current Liabilities sank 80.55% in 2023 and surged 8913.23% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $2.5 million in 2022, then tumbled by 64.0% to $900000.0 in 2023, then soared by 1242.22% to $12.1 million in 2024, then jumped by 4683.69% to $577.9 million in 2025, then climbed by 23.42% to $713.2 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $713.2 million in Q2 2026, $648.7 million in Q1 2026, and $577.9 million in Q4 2025.